Kornimate/medical-research-clean huggingface dataset:
pet imaging study of recovered anorexics

Conditions: Anorexia Nervosa

Summary: several studies in the past suggest that individuals who have or had anorexia nervosa may have alterations in brain serotonin. serotonin seems to play an important role in regulating anxiety, mood, and other symptoms found in anorexia nervosa. we will be using a technology called positron emission tomography (pet), which is a method used to take pictures of the body, in this case, the brain. study participants will undergo two baseline pet scans on the first day of the study. the women who have recovered from anorexia will then be given a medication called fluoxetine (also know as prozac) to take for 8 weeks. at the end of the 8th week, they will return for a third pet scan. by comparing the brain scans, before and after fluoxetine treatment, we can understand more about how treatment with fluoxetine affects the serotonin receptors in the brain. we will be comparing brain serotonin system in women who have recovered from anorexia before and after medication in order to gain a better understanding of changes in the serotonin system associated with eating disorders. this study may help shed light on how to make fluoxetine a more effective treatment for anorexia nervosa.


Eligibility criteria:
inclusion criteria: * recovered from anorexia nervosa * not taking medication for emotional problems * regular menstrual cycle exclusion criteria: * women who are pregnant or nursing * psychoactive medications in the past 30 days * neurological disorders.

Keywords: eating disorders anorexia nervosa anorexia pet brain imaging serotonin fmri prozac fluoxetine
group and mobile care for gestational diabetes

Conditions: Gestational Diabetes

Summary: a critical variation in the provision of prenatal care to women with gdm is the need to keep patients engaged with their care between visits by tracking glucose levels using finger sticks and making dietary and other lifestyle modifications to keep these levels at or close to normal. multiple studies have demonstrated that the use of mobile devices can improve medical outcomes. in order to keep patients engaged between appointments and improve self-care/lifestyle, we will study the use of a glucose monitoring system with nutrition therapy called glucosemama(gm). gm is a mobile app on the ios system that individuals with gdm will use to tract blood sugars and number of carbs consumed. in addition, it will give the user positive feedback and rewards for using the system. this model of group care with mobile phone monitoring and reminders for women with gdm has not been previously studied. a randomized control trial is purposed to determine if this approach improves patient care. the investigators hypothesize that group prenatal care along with inter-session mobile therapy will increase dietary compliance and therefore reduce the number of individuals requiring pharmacologic therapy and improve neonatal outcomes during pregnancy. group prenatal care (gpc) will provide a community foundation to improve learning and increase the motivation of patients to learn and change. this motivation will be further strengthened by the use of the glucosemama monitoring system which will provide each patient with glucose tracking and individualized nutritional support.


Eligibility criteria:
inclusion criteria: * diagnosis of gestational diabetes * planning on delivering at home institution exclusion criteria: * unwilling to participate.
methylene blue versus vasopressin analogue for treatment of septic shock in preterm neonate

Conditions: Neonatal Sepsis; Refractory Shock

Summary: a randomized, prospective study comparing methylene blue versus terlipressin in treatment of catecholamines resistant shock in preterm neonate

the study will be an un-blinded, phase 2, randomized, 1:1, prospective trial comparing methylene blue versus terlipressin in treatment of preterm neonate with catecholamines resistant septic shock the outcome as regard elevation of mean arterial blood pressure will be measured within 72 hours

Eligibility criteria:
neonate with gestational age at birth ≤ 36weeks inclusion criteria: * diagnosis of septic shock according to clinical sepsis score of tollner and hematologic scoring system of rodwell * refractory septic shock defined as hypotension although adequate fluid resuscitate and high dose vasopressor(ne \>0.5 mcg/kg/min) * consent form exclusion criteria: * known case of g6pd deficiency * hx of drug allergy mb, ne, terlipressin * patients with severely impaired renal function. * history of maternal drug intake of selective serotonin reuptake inhibitors,and serotonin-norepinephrine reuptake inhibitors

Keywords: methylene blue terlipressin septic shock preterm neonate
new options for treating knee osteoarthritis pain

Conditions: Knee Osteoarthritis

Summary: this study will be a single-site, four-arm, randomized, placebo-controlled clinical trial. knee osteoarthritis patients (n=164) will be randomized to reiki, sham reiki (placebo control), mindfulness meditation (active control), or a waitlist control condition. the three active interventions will be applied for 20 minutes, once a week, for four consecutive weeks in a university laboratory setting.


Eligibility criteria:
inclusion criteria: * osteoarthritis in at least one knee * report a womac pain score average \>/= 2 * not using any kind of energy therapy different from the proposed study * ability to read, understand and speak english exclusion criteria: * knee arthroplasty in the previous year * have cognitive impairment as determined by clinical interview
association of thoraco-mediastinal radiotherapy with maintenance immunotherapy treatment with atezolizumab

Conditions: Small Cell Lung Cancer

Summary: investigate the role of consolidative radiotherapy treatment at the thoraco-mediastinal level in the patient suffering from lung microcytoma - extensive disease and treated with chemo-immunotherapy with atezolizumab, in association with maintenance therapy with atezolizumab.

prospective phase ii study on patients affected by extensive-stage small cell lung cancer. the traditional treatment of lung microcytoma-extensive disease consists in platinum and etoposide-based chemotherapy. radiotherapy of consolidation at the thoracic mediastinal level after chemotherapy may have an impact on survival and can be offered to patients in response to chemotherapy. studies have recently shown that the addition of immunotherapy with atezolizumab to traditional chemotherapy improves survival compared to placebo. however, the use of consolidation radiotherapy was not permitted in the study thoracic level. therefore the objective is to evaluate the efficacy and tolerance of the thoracic radiotherapy-immunotherapy association in the maintenance phase with atezolizumab of the treatment of lung microcytoma - extensive disease treated with chemo-immunotherapy.

Eligibility criteria:
inclusion criteria: * histological diagnosis of lung microcytoma; * age ≥18 years; * performance status according to ecog 0-2; * extended disease at the time of first line oncological treatment; * initial staging and restaging after chemo-immunotherapy with ct, ct-pet fdg and brain mri; * in at least partial response (defined according to the recist criteria \[18\]) after treatment chemoimmunotherapy according to the impower 133 scheme; * haematological, respiratory toxicity ≤ g1, other toxicities ≤ g2 at the time of treatment radiotherapy; * pulmonary function tests at the time of radiotherapy treatment compatible with irradiation: fev≥1.2 l or \>40%, dlco≥50%; * written informed consent. exclusion criteria: * previous radiotherapy treatment at the thoraco-mediastinal level; * in disease progression after chemo-immunotherapy treatment.
study using the shiratronics migraine therapy system

Conditions: Chronic Migraine, Headache

Summary: the purpose of this pilot study is to assess the preliminary safety and efficacy of the shiratronics migraine therapy system in prophylactic treatment of patients with refractory chronic migraine.


Eligibility criteria:
inclusion criteria: 1. participants who are 22 years of age or older. 2. history of migraine ≥ 12 months. 3. participants experiencing between 15 to 26 headache days per month, with at least 8 headache days (per month) with migraine phenotype presentation. 4. inadequate response to, unwilling, or contraindicated to onabotulinumtoxin a and cgrp monoclonal antibodies therapy. 5. stable use of migraine medication. exclusion criteria: 1. post-traumatic headache. 2. medication overuse headache. 3. new daily persistent headache. 4. report experiencing unremitting, continuous headaches with no relief. 5. previously implanted neurostimulator to treat headache. 6. history of cervical radiofrequency ablation or had any other intervention/device for migraine.
impact of additional treatment with saccharomyces boulardii on quality of life in patients with mild forms of ulcerative colitis and crohn disease

Conditions: Ulcerative Colitis; Crohn Disease

Summary: the goal of the study is to assess the impact of treatment with dietary supplement containing saccharomyces boulardii (used as an addition to standard therapy), on quality of life of patients with mild forms of ulcerative colitis and crohn disease, as well as those in remission fulfilling criteria for irritable bowel syndrome. patients included will be randomly assigned in two groups and subsequently administered with formulation containing saccharomyces boulardii or placebo for 4 weeks. patient's quality of life will be assessed by questionnaire at the enrolment and 4 weeks after initiating the therapy.

saccharomyces boulardii has been reported to have positive impact on intestinal epithelial barrier as well as immune system. it has been proven to be efficient in treatment and prophylaxis of travellers diarrhoea, hiv associated diarrhoea, antibiotics associated diarrhoea and clostridium difficile infection. however there is a limited data available on effect of therapy with saccharomyces boulardii (as add-on to standard therapy) in patients with inflammatory bowel disease. nevertheless, knowing the effect saccharomyces boulardii has on intestinal flora, intestinal epithelium and immune system it can be hypothesised that saccharomyces boulardii used as add-on to standard therapy in ibd patients can lead to improvement in symptoms and therefore in quality of life.

Eligibility criteria:
inclusion criteria: * histological diagnosis of ulcerative colitis or crohn disease * colonoscopy in last six months confirming mild disease form according to endoscopic criteria (mayo score, simple endoscopic score) * colonoscopy in last six months confirming endoscopic remission with fulfilled clinical rome iv criteria for irritable bowl syndrome * patients * patients with mild disease form are eligible only if treated with mesalazine only * patients in remission eligible for inclusion if treated with mesalazine, biologics, azathioprine or methotrexate * signed informed consents exclusion criteria: * no colonoscopy in last six months * moderate to severe disease according to colonosopy findings (mayo score, simple endoscopic score) * indeterminate colitis

Keywords: saccharomyces boulardii
hypofractionated intensity modulated chemoradiotherapy to treat locally advanced non-small cell lung cancer

Conditions: Stage III Non-Small Cell Lung Cancer

Summary: locally advanced non-small cell lung cancer can be treated successfully with chemotherapy and radiation. however, the cure rate is low. this study is carried out to find out whether giving radiotherapy at a higher dose over fewer treatment sessions with intensity modulated radiotherapy (imrt) can improve the treatment outcome. this study aims to recruit 43 patients from national university hospital and tan tock seng hospital over a period of about 2 years.


Eligibility criteria:
inclusion criteria: * pathologically proven (either histologic or cytologic) diagnosis of stage iiia or iiib non-small cell lung cancer; excluding patients with n3 disease based on supraclavicular or contralateral hilar adenopathy, or significant pleural / pericardial effusion. exclusion criteria: * patients for whom treatment is planned with a maximum dose of ≥ 66 gy to the ipsilateral brachial plexus * greater than minimal, exudative, or cytologically positive pleural effusions * ≥ 10% weight loss within the past month * prior invasive malignancy (with exceptions) * prior radiotherapy to the region of the study cancer * significant co-morbidities * pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception * known allergic reactions to components of planned chemotherapy regimen
respiratory management of preterm infants and bronchopulmonary dysplasia

Conditions: Bronchopulmonary Dysplasia

Summary: this observational study evaluates the impact of respiratory management modifications implemented in our institution on the intubation rates and the death or bronchopulmonary dysplasia (bpd) outcome.

less invasive respiratory management has been implemented in most neonatal units as well as lung protective ventilatory strategies when intubation is required in order to minimize ventilator induced lung injury. in our institution a new ventilatory protocol including less invasive surfactant administration, synchronized nasal positive pressure ventilation and early rescue high frequency ventilation has been implemented during 2013-14. hypothesis: new less invasive and lung protective strategies to prevent lung injury had been effective in reducing intubation rates.

Eligibility criteria:
inclusion criteria: all preterm infants born with less than 32wga admitted in our nicu. exclusion criteria: congenital malformations and known chromosomal disorders,

Keywords: lung protective strategies less invasive respiratory support preterm infant
efficacy and safety study of protein c concentrate in subjects with severe congenital protein c deficiency

Conditions: Protein C Deficiency

Summary: the purpose of this study is to show that protein c concentrate is a safe and effective treatment for subjects with congenital protein c deficiency. depending on the type of treatment required, patients are assigned to one of 3 study parts: part 1 is for the treatment of acute episodes, part 2 is for short-term prophylaxis, and part 3 is for long-term prophylaxis in infants aged less than 6 months only.


Eligibility criteria:
inclusion criteria: * newborn subjects \<= 6 months of age: diagnosis of severe congenital protein c deficiency, with documented functional protein c level \< 20%. if a genetic diagnosis is not available prior to initiation of protein c concentrate treatment, a documented family history of protein c deficiency is required. * subjects \> 6 months of age: confirmed diagnosis of severe congenital protein c deficiency, i.e., by * a genetic analysis of severe congenital protein c deficiency (i.e., homozygous or double heterozygous) or * a documented family history of protein c deficiency and a documented functional protein c level \< 20% while the subject is in an asymptomatic state and not receiving oral anticoagulation therapy * signed and dated informed consent from either the subject or the subject's legally authorized representative prior to enrollment. informed consent includes consent for conducting a genetic analysis (if the genetic defect is unknown). exclusion criteria: * subjects with a history of allergic reactions to protein c concentrate. in the case of allergic reactions occurring at the protein c concentrate injection site; exclusion from the study is at the discretion of the investigator but should be reported as an ae regardless of the subject's inclusion in or exclusion from the study. * participation in any clinical study in which another investigational agent is used within 30 days prior to enrollment or its use is expected at any time for the duration of study participation.

Keywords: severe congenital protein c deficiency
double blind atorvastatin amlodipine study

Conditions: Angina

Summary: to evaluate and compare the safety and efficacy of amlodipine, atorvastatin and the combination in patients with symptomatic myocardial ischemia. amlodipine's use in angina has been well documented in clinical trials such as the circadian anti-ischemia program in europe (cape), but the impact on vascular inflammation in clinical practice has not been tested. furthermore, the potentially synergistic benefit of atorvastatin and amlodipine on inflammation ischemic activity has not been studied.


Eligibility criteria:
inclusion criteria: * holter monitoring at baseline which demonstrates a total of 15 minutes of ischemia and/or 3 ischemic events per 48 hours. * total cholesterol \> 5.2 mmol/l (200 mg/dl) on diet alone. exclusion criteria: * myocardial infarction within 2 months prior to the study. * likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
immunogenicity and safety of dtap or dt vaccine in 6 year old children

Conditions: Vaccine Reaction

Summary: this study is to evaluate the immunogenicity and safety of dtap or dt given in children aged 6 years.

a phase 4 trial was conducted in zhejiang province aimed to evaluate the immunogenicity and safety of dtap or dt in children aged 6 years. dtap and dt are produced by wuhan biological products co., ltd. participants will be recruited and randomly divided into two groups to receive dtap or dt in 1:1 ratio. two blood samples were taken on day 0 (pre-vaccination) and day 28\~42 (after-vaccination) for test antibody against pertussis, diphtheria and tetanus. adverse events and serious adverse events were actively collected by staff within 28 days of vaccination.

Eligibility criteria:
inclusion criteria: 1. participants aged ≥ 6 on the day of enrollment; 2. informed consent should be signed and dated by the participants; 3. the participant's legal guardian is able to attend all planned follow-up visits and comply with all study procedures; 4. the participants have received 4 doses of acellular tdap vaccine and have not received any immunization agents related to diphtheria, tetanus, and pertussis in the past 3 years; 5. the participant has no diease history of pertussis, diphtheria or tetanus; 6. ≥ 14 days interval between the last vaccination; 7. body temperature was ≤37.3℃. exclusion criteria: 1. being allergic to any component of vaccines ； 2. a history of severe allergic reactions to any vaccine (for example acute allergic reaction, angioneurotic edema, dyspnea, etc）； 3. having a history or family history of convulsions, encephalopathy, psychosis, uncontrolled epilepsy and other progressive neurological diseases; 4. participants are suffering from immunodeficiency, receiving immunosuppressant therapy (oral steroid hormones) during treatment for malignancy, or having low immunity due to hiv, or having congenital immune disorders in close family members; 5. injection of non-specific immunoglobulin within 1 month before enrollment; 6. participants are suffering from acute febrile diseases and infectious diseases; 7. a history of clearly diagnosed thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection; 8. participants with severe chronic diseases or acute episodes of chronic diseases; 9. participants with infectious, suppurative and allergic skin diseases; 10. other participants whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies.

Keywords: immunogenicity，safety，dtap，dt
bone microarchitecture abatacept (bma2)

Conditions: Arthritis, Rheumatoid

Summary: rheumatoid arthritis patients management reposes primarily on the use of disease-modifying antirheumatic drugs (dmards). among dmards available in 2015, researchers demonstrated the ability to reduce synovitis, biomarkers of inflammation, and bone destruction. given the demonstration of correlation between joint inflammation and structural progression at each joint level as well as the opportunity for bone remodeling with resolution of joint inflammation, researchers expect to observe an improvement in bone micro-architecture parameters specifically in rheumatoid arthritis patients without remaining joint inflammation 3 months following abatacept treatment initiation.

rheumatoid arthritis patients management reposes primarily on the use of disease-modifying anti-rheumatic drugs. in patients responding insufficiently to methotrexate, and/or other disease-modifying anti-rheumatic drugs (dmard) strategies, with or without glucocorticoids, biological dmard (tnf inhibitors, abatacept or tocilizumab, and, under certain circumstances, rituximab) should be commenced with methotrexate. among dmard available in 2015, abatacept has demonstrated the ability to reduce synovitis, biomarkers of inflammation, and bone destruction. monitoring rheumatoid arthritis patients after starting abatacept by us exams observed a strong reduction of power doppler ultra-sonography at 3 months in two third of patients. given the demonstration of correlation between joint inflammation and structural progression at each joint level as well as the opportunity for bone remodeling with resolution of joint inflammation, researchers expect to observe an improvement in bone micro-architecture parameters specifically in rheumatoid arthritis patients without remaining joint inflammation 3 months following abatacept initiation.

Eligibility criteria:
inclusion criteria: * signed and dated informed consent form, * age ≥ 18 years, * rheumatoid arthritis diagnosis according to acr/eular 2010 criteria * abatacept therapy sub-cutaneous required according eular recommendations * patients affiliated to health insurance exclusion criteria: * other arthritis than rheumatoid arthritis, * contraindication to abatacept, * concomitant treatment with zoledronic acid (aclasta®) or denosumab (prolia®), * injection intravenously or intra-articular at the 2nd and 3rd metacarpophalangeal joint of the dominant hand during the 3 months prior to inclusion, * prior or planned joint surgery at the 2nd or 3rd metacarpophalangeal joint of the dominant hand over the one year study, * no recent used of high density contrast material, * pregnancy or breastfeeding.